Market Overview

UPDATE: Wedbush Raises PT to $34 on Medifast on Increased Management Confidence

Share:
Related MED
Morning Market Losers
FXCM, Jamba Lead After-Hours Movers On Thursday

Wedbush reiterated its Outperform rating on Medifast (NYSE: MED) and raised its price target from $26 to $34.

Wedbush noted, "In meetings with investors last week, management reiterated its previously announced plans to grow sales to $1 billion, for which, detailed plans to achieve this goal will be announced later this year, and noted it was exploring several alternative opportunities to quickly penetrate new markets in both the U.S. and internationally. Growth will be aided by the company's brand-building efforts, such as national radio advertising during Notre Dame football games this fall. Management also plans to improve the profitability of each business, with a sharp improvement in weight control center profitability already displayed in Q2."

Medifast closed at $28.52 on Friday.

Latest Ratings for MED

DateFirmActionFromTo
Mar 2015Bank of AmericaDowngradesNeutralUnderperform
Nov 2014Imperial CapitalDowngradesOutperformIn-line
Nov 2014Canaccord GenuityMaintainsHold

View More Analyst Ratings for MED
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (MED)

Around the Web, We're Loving...

Get Benzinga's Newsletters